Corcept Therapeutics is trading at $83.00, up 4.77%, amid broad-market gains; no company-specific catalyst for the November 4 after-hours rise was identified.
- Q3 revenue was $340.5 million, up 64% year over year; Lifyorli revenue was $91.4 million.
- Management reiterated 2026 revenue guidance of $1.1–$1.2 billion; investors had reacted cautiously to the unchanged outlook after the earnings release.
- On November 4, the S&P 500 rose 1.66% and Nasdaq Composite rose 1.88%; broad-market gains are the likeliest context, not a confirmed catalyst.